Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Giant Biogene Holding (2367.HK)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (HK$)	Price Target (HK$)	Rating
2022-03-18	NaN	-	No Rating
2023-08-29	36.75	43.30	Buy
2024-01-15	35.95	44.90	Buy
2024-03-12	40.30	57.06	Buy
2024-03-26	42.50	56.18	Buy
2024-07-16	40.45	62.40	Buy
2024-08-21	39.65	63.50	Buy
2025-03-10	68.85	82.00	Buy
2025-04-07	60.90	80.60	Buy
2025-05-07	78.80	93.10	Buy

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.